GlassScriptPhysician profile
Brett Dolgin
NPI 1417206459
$20,168.32
in general payments reported to CMS, 2019-2025
37 companies · $4,622 in 2025
The $4,622 reported for 2025 was more than what 88% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,155 · 2020: $1,006 · 2021: $1,777 · 2022: $2,808 · 2023: $3,272 · 2024: $4,529 · 2025: $4,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,193.18 |
| Education | $230.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,843.80 | 2019-2025 | Tremfya, Simponi, Stelara |
| Novartis Pharmaceuticals Corporation | $2,401.34 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $2,134.56 | 2023-2025 | Zoryve |
| Abbvie INC. | $1,551.90 | 2019-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $1,341.95 | 2019-2025 | Absorica Ld, Winlevi |
| Leo Pharma INC. | $1,271.66 | 2020-2025 | Adbry, Anzupgo |
| Ucb, INC. | $937.67 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $911.06 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $859.47 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $853.11 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $847.73 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Incyte Corporation | $777.88 | 2021-2025 | Opzelura |
| Genzyme Corporation | $716.43 | 2019-2025 | |
| Pfizer INC. | $522.07 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $521.38 | 2019-2025 | Siliq, Targretin, Duobrii |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $383.19 | 2021-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.66 | 2023-2025 | Spevigo, Cyltezo |
| Biofrontera INC. | $118.40 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Journey Medical Corporation | $112.87 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| Dermira, INC. | $98.96 | 2019-2020 | |
| Medimetriks Pharmaceuticals, INC. | $84.73 | 2020 | |
| Organon LLC | $64.71 | 2025 | Vtama |
| Genentech USA, INC. | $61.47 | 2019-2023 | Erivedge |
| Paratek Pharmaceuticals, INC. | $60.10 | 2020-2024 | Nuzyra |
| Celgene Corporation | $56.42 | 2019 | |
| Verrica Pharmaceuticals INC. | $52.05 | 2024 | Ycanth |
| Mayne Pharma Commercial LLC | $42.69 | 2023 | |
| Kyowa Kirin, INC. | $39.85 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $39.47 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $32.61 | 2019-2020 | |
| Dusa Pharmaceuticals, INC. | $21.43 | 2019 | |
| Botanix Sb INC | $20.97 | 2025 | Sofdra |
| Almirall LLC | $16.44 | 2023 | Klisyri |
| Lnhc, INC | $16.36 | 2025 | Zelsuvmi |
| Merck Sharp & Dohme LLC | $12.58 | 2019 | |
| Strata Skin Sciences, INC. | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Dolgin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.